Biotechnology firm focused on cancer therapeutic development,, has received a United States patent grant for the company’s anti-cancer compound, VAL201.
This morning’s announcement follows ValiRx’s earlier statement on 26 June 2019 which saw the US Patent and Trademark Office allow patent claims for the use of VAL201 in the prevention and treatment of metastatic (including prostate) cancer.
The VAL201 compound is currently undergoing clinical trials for the treatment of prostate cancer and potentially other indications of hormone induced unregulated growth including endometriosis.
The grant, covering one of ValiRx’s largest commercial markets, will provide patent protection to regulate symptoms of metastatic cancer which occurs when the disease spreads from its site of origin to other parts of the body.
Shares in ValiRx were trading 3.85% higher at 0.135p during Thursday morning.
The patent works to prevent the worsening of symptoms, reduce progression and even treat this type or underlying cancer via administration of the VAL201 peptide.
VL201 prevents tumour growth “selectively” by inhibiting the proliferation of tumour cells, the company explained.
The compound’s clinical trials have so far “met its endpoints very well” allowing ValiRx to use the peptide to demonstrate VL201 as a therapeutic product in what is considered “a poorly-served, yet very substantial commercial market.”
Dr Satu Vainikka, CEO of ValiRx said that the US patent grant represents “a key addition” to the group’s patent coverage and protection for this indication.
Dr Vainikka further demonstrated the validation of ValiRx’s potential anti-cancer impact under the basis that all primary cancers have the ability to metastasise and spread to other parts of the body at any point.
Follow News & Updates from ValiRx here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
Majid Shafiq, CEO of i3 Energy (AIM:I3E), and CFO, Graham Heath, discuss today’s follow-on deal to sell the Gain assets to Harvard Resources which will occur following the completion of the group’s previously announced C$80 million reverse takeover .
i3 Energy plc, an independent oil and gas company with assets and operations in the UK, Final Results for the year ended 31 December 2019 show significant operational progress for the pre-revenue company with net loss of £10.8m. To fund the Gain acquisition announced post period end in 2020, i3 is proposing to raise £30 million at a price of 5 pence per share, an 18% discount to the closing mid-price at which i3's shares suspended on 23 June 2020.
Oilex, the Operator of the PSC and on behalf of the JDPA joint venture, has reached amicable settlement with JPDA in East Timor with a settlement of US$0.8m payable in 2021 and 2022 financial years. The settlement amount is fully provided for in the FY19 accounts.
Avacta Group has entered into a collaboration with the Liverpool School of Tropical Medicine to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing in conjunction with Cytiva.
Shield Therapeutics said a reanalysis of the AEGIS-H2H study for its iron deficiency lead product Feraccru®/Accrufer® has confirmed the product as a credible alternative to IV therapy for patients with iron deficiency anaemia.